# schizophrenia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/schizophrenia

> 30 upcoming FDA catalysts in schizophrenia: lb-102 (50 mg tablet, LBRX) on June 2027 (primary completion); lb-102 (50 mg tablet, LBRX) on Jun to Sep 2027 (topline data readout); GXV813 (NVS) on Jul to Oct 2027 (topline data readout); GXV813 (NVS) on July 2027 (primary completion); and 26 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 30, 2023 | [Brilaroxazine topline data readout](https://sec-api.dev/pdufa/brilaroxazine) | RVPH | schizophrenia | completed, positive | "On October 30, 2023, we announced positive topline results and successful completion of our pivotal RECOVER-1 Trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774925034827/rvph20250930_10q.htm)) |
| Aug 2024 | [Direclidine topline data readout](https://sec-api.dev/pdufa/direclidine) | NBIX | schizophrenia | completed, positive | "In August 2024, we announced positive top-line data from the Phase 2 clinical study of NBI-1117568 in adults with schizophrenia." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/914475/000091447525000037/nbix-20241231.htm)) |
| December 16, 2024 | [Brilaroxazine interim data readout](https://sec-api.dev/pdufa/brilaroxazine) | RVPH | schizophrenia | completed, positive | "On December 16, 2024, we announced positive preliminary topline data from, and on June 2, 2025, we announced a positive full dataset and successful completion of, our Phase 3 RECOVER open label extension (the "OLE" or the "OLE Trial") a 1-year study evaluating the long-term safety, tolerability and efficacy of brilaroxazine in patients with schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774925034827/rvph20250930_10q.htm)) |
| June 25, 2025 | [Emraclidine primary completion](https://sec-api.dev/pdufa/emraclidine) | ABBV | Schizophrenia | withdrawn | "NCT05443724 (A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-06-25 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-08-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05443724)) |
| June 2025 | [Anavex3-71 oral capsules primary completion](https://sec-api.dev/pdufa/anavex3-71-oral) | AVXL | Schizophrenia | delayed | "NCT06245213 (A Study of ANAVEX3-71 in Adults With Schizophrenia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-06-30 (ESTIMATED); Lead Sponsor Anavex Life Sciences Corp.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06245213)) |
| March 25, 2026 | [Xanomeline and trospium chloride capsules primary completion](https://sec-api.dev/pdufa/xanomeline-and-trospium) | BMY | Schizophrenia | completed | "NCT05304767 (An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05304767)) |
| June 4, 2026 | [Ml-007c-ma bid primary completion](https://sec-api.dev/pdufa/ml-007c-ma-bid) | MPLT | Schizophrenia | completed | "NCT07038876 (A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-04 (ACTUAL); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07038876)) |
| June 2027 | [Lb-102 (50 mg tablet) primary completion](https://sec-api.dev/pdufa/lb-102) | LBRX | Schizophrenia | scheduled | "NCT07363577 (Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor LB Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363577)) |
| Jun to Sep 2027 | [Lb-102 (50 mg tablet) topline data readout](https://sec-api.dev/pdufa/lb-102) | LBRX | Schizophrenia | scheduled | "NCT07363577 (Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor LB Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363577)) |
| Jul to Oct 2027 | [GXV813 topline data readout](https://sec-api.dev/pdufa/gxv813) | NVS | Schizophrenia | scheduled | "NCT07467993 (Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07467993)) |
| July 2027 | [GXV813 primary completion](https://sec-api.dev/pdufa/gxv813) | NVS | Schizophrenia | scheduled | "NCT07467993 (Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07467993)) |
| August 2027 | [NBI-1117570 primary completion](https://sec-api.dev/pdufa/nbi-1117570) | NBIX | Schizophrenia | scheduled | "NCT07288333 (Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288333)) |
| Aug to Nov 2027 | [NBI-1117570 topline data readout](https://sec-api.dev/pdufa/nbi-1117570) | NBIX | Schizophrenia | scheduled | "NCT07288333 (Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288333)) |
| October 2027 | [NBI-1117568 primary completion](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT06963034 (NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963034)) |
| Oct 2027 to Jan 2028 | [NBI-1117568 topline data readout](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT06963034 (NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963034)) |
| November 2027 | [Fanapt® (iloperidone) primary completion](https://sec-api.dev/pdufa/iloperidone) | VNDA | Schizophrenia | scheduled | "NCT06961968 (Randomized Withdrawal Study in Patients With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961968)) |
| Nov 2027 to Feb 2028 | [Fanapt® (iloperidone) topline data readout](https://sec-api.dev/pdufa/iloperidone) | VNDA | Schizophrenia | scheduled | "NCT06961968 (Randomized Withdrawal Study in Patients With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961968)) |
| November 2027 | [NBI-1117568 primary completion](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT07105098 (NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07105098)) |
| Nov 2027 to Feb 2028 | [NBI-1117568 topline data readout](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT07105098 (NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07105098)) |
| November 2027 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Schizophrenia | scheduled | "NCT07410507 (A Study of Brenipatide in Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07410507)) |
| Nov 2027 to Feb 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Schizophrenia | scheduled | "NCT07410507 (A Study of Brenipatide in Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07410507)) |
| February 2028 | [Emraclidine primary completion](https://sec-api.dev/pdufa/emraclidine) | ABBV | Schizophrenia | scheduled | "NCT07145918 (A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07145918)) |
| Feb to May 2028 | [Emraclidine topline data readout](https://sec-api.dev/pdufa/emraclidine) | ABBV | Schizophrenia | scheduled | "NCT07145918 (A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07145918)) |
| Sep to Dec 2028 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia | scheduled | "NCT06882785 (A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-23 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06882785)) |
| September 2028 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia | scheduled | "NCT06882785 (A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-23 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06882785)) |
| December 2028 | [Lb-102 (50 mg tablet) primary completion](https://sec-api.dev/pdufa/lb-102) | LBRX | Schizophrenia | scheduled | "NCT07369154 (52-week Open Label Safety-Tolerability Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor LB Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07369154)) |
| Dec 2028 to Mar 2029 | [Lb-102 (50 mg tablet) topline data readout](https://sec-api.dev/pdufa/lb-102) | LBRX | Schizophrenia | scheduled | "NCT07369154 (52-week Open Label Safety-Tolerability Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor LB Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07369154)) |
| Dec 2028 to Mar 2029 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Schizophrenia | scheduled | "NCT07680946 (Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07680946)) |
| December 2028 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Schizophrenia | scheduled | "NCT07680946 (Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07680946)) |
| Mar to Jun 2029 | [Xanomeline/trospium chloride topline data readout](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Schizophrenia | scheduled | "NCT07686263 (Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686263)) |
| March 2029 | [Xanomeline/trospium chloride primary completion](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Schizophrenia | scheduled | "NCT07686263 (Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686263)) |
| July 2029 | [NBI-1117568 primary completion](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT07227818 (Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07227818)) |
| Jul to Oct 2029 | [NBI-1117568 topline data readout](https://sec-api.dev/pdufa/nbi-1117568) | NBIX | Schizophrenia | scheduled | "NCT07227818 (Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07227818)) |
| Dec 2029 to Mar 2030 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia | scheduled | "NCT07288567 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288567)) |
| December 2029 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia | scheduled | "NCT07288567 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288567)) |
| February 2030 | [ML-007C-MA primary completion](https://sec-api.dev/pdufa/ml-007c-ma) | MPLT | Schizophrenia | scheduled | "NCT07459647 (A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459647)) |
| Feb to May 2030 | [ML-007C-MA topline data readout](https://sec-api.dev/pdufa/ml-007c-ma) | MPLT | Schizophrenia | scheduled | "NCT07459647 (A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459647)) |

## Drugs

- [Brilaroxazine](https://sec-api.dev/pdufa/brilaroxazine) (RVPH)
- [Direclidine](https://sec-api.dev/pdufa/direclidine) (NBIX)
- [Emraclidine](https://sec-api.dev/pdufa/emraclidine) (ABBV)
- [Anavex3-71 oral capsules](https://sec-api.dev/pdufa/anavex3-71-oral) (AVXL)
- [Xanomeline and trospium chloride capsules](https://sec-api.dev/pdufa/xanomeline-and-trospium) (BMY)
- [Ml-007c-ma bid](https://sec-api.dev/pdufa/ml-007c-ma-bid) (MPLT)
- [Lb-102 (50 mg tablet)](https://sec-api.dev/pdufa/lb-102) (LBRX)
- [GXV813](https://sec-api.dev/pdufa/gxv813) (NVS)
- [NBI-1117570](https://sec-api.dev/pdufa/nbi-1117570) (NBIX)
- [NBI-1117568](https://sec-api.dev/pdufa/nbi-1117568) (NBIX)
- [Fanapt® (iloperidone)](https://sec-api.dev/pdufa/iloperidone) (VNDA)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)
- [ML-007C-MA](https://sec-api.dev/pdufa/ml-007c-ma) (MPLT)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/schizophrenia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "schizophrenia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/schizophrenia

```bibtex
@misc{secapidev_indications_schizophrenia_20261116,
  title        = {schizophrenia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/schizophrenia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_schizophrenia_20261116","title":"schizophrenia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/schizophrenia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
